Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis

Oncotarget

Volumn 6, Issue 40, 2015, Pages 42733-42748

  Chang, Yao Wen ^a   Hsieh, Pei Wen ^a   Chang, Yu Tsui ^a   Lu, Meng Hong ^a   Huang, Tur Fu ^b   Chong, Kowit Yu ^a,c   Liao, Hsiang Ruei ^a   Cheng, Ju Chien ^d   Tseng, Ching Ping ^a,c,e  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Platelet aggregation; Podoplanin; TCIPA; Tumor metastasis

Indexed keywords

2CP; CISPLATIN; NITROBENZOIC ACID DERIVATIVE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PODOPLANIN; PROTEIN AKT1; PROTEIN CLEC 2; PROTEIN KINASE C MU; PROTEIN KINASE SYK; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; CLEC2B PROTEIN, HUMAN; LECTIN; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULAR MODEL; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SURFACE PLASMON RESONANCE; THROMBOCYTE; THROMBOCYTE AGGREGATION; TUMOR INVASION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; BLOTTING, WESTERN; HUMANS; LECTINS, C-TYPE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM INVASIVENESS; NITROBENZOATES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SURFACE PLASMON RESONANCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84952359714     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5811     Document Type: Article

References (69)

1. Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest. 2004; 114:1691-1693.
2. Stenger D, Dutting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014; 133:S149-157.
3. Jurasz P, Stewart MW, Radomski A, Khadour F, Duszyk M, Radomski MW. Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. Br J Pharmacol. 2001; 134:1104-1112.
4. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004; 143:819-826.
5. Erpenbeck L, Schon MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010; 115:3427-3436.
6. Lian L, Li W, Li ZY, Mao YX, Zhang YT, Zhao YM, Chen K, Duan WM, Tao M. Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs. Oncol Lett. 2013; 5:675-680.
7. Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol. 2004; 141:241-252.
8. Medina C, Harmon S, Inkielewicz I, Santos-Martinez MJ, Jones M, Cantwell P, Bazou D, Ledwidge M, Radomski MW, Gilmer JF. Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin. Br J Pharmacol. 2012; 166:938-949.
9. Cohen SA, Trikha M, Mascelli MA. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res. 2000; 6:163-174.
10. Amirkhosravi A, Mousa SA, Amaya M, Blaydes S, Desai H, Meyer T, Francis JL. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003; 90:549-554.
11. Radomski A, Jurasz P, Sanders EJ, Overall CM, Bigg HF, Edwards DR, Radomski MW. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol. 2002; 137:1330-1338.
12. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23:2130-2135.
13. Lian L, Li W, Li ZY, Mao YX, Zhang YT, Zhao YM, Chen K, Duan WM, Tao M. Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs. Oncol Lett. 2013; 5:675-680.
14. Xu Y, Ogose A, Kawashima H, Hotta T, Ariizumi T, Li G, Umezu H, Endo N. High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis. Oncol Rep. 2011; 25:599-607.
15. Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012; 3:283.
16. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T, Fujita N. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol. 2007; 170:1337-1347.
17. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007; 282:25993-26001.
18. Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt AY, Fenton-May AE, Johnson LA, Jackson DG, Watson SP, O'Callaghan CA. Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J. 2008; 411:133-140.
19. Ozaki Y, Suzuki-Inoue K, Inoue O. Novel interactions in platelet biology: CLEC-2/podoplanin and laminin/GPVI. J Thromb Haemost. 2009; 7:191-194.
20. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost. 2010; 8:1456-1467.
21. Severin S, Pollitt AY, Navarro-Nunez L, Nash CA, Mourao-Sa D, Eble JA, Senis YA, Watson SP. Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. J Biol Chem. 2011; 286:4107-4116.
22. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost. 2011; 9:44-55.
23. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007; 96:1-5.
24. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res. 2008; 28:2997-3006.
25. Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One. 2013; 8:e73609.
26. Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, Shin Y, Hirashima M, Ozaki Y. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem. 2010; 285:24494-24507.
27. Hsieh PW, Chang YT, Chuang WY, Shih HC, Chiang SZ, Wu CC. The synthesis and biologic evaluation of anti-platelet and cytotoxic beta-nitrostyrenes. Bioorg Med Chem. 2010; 18:7621-7627.
28. Hsieh PW, Chiang SZ, Wu CC, Lo YC, Shih YT, Wu YC. Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs. Bioorg Med Chem. 2008; 16:5803-5814.
29. Hsieh PW, Hwang TL, Wu CC, Chiang SZ, Wu CI, Wu YC. The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents. Bioorg Med Chem Lett. 2007; 17:1812-1817.
30. Wang WY, Hsieh PW, Wu YC, Wu CC. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007; 74:601-611.
31. Wang WY, Wu YC, Wu CC. Prevention of platelet glycoprotein IIb/IIIa activation by 3, 4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol. 2006; 70:1380-1389.
32. Amirkhosravi A, Mousa SA, Amaya M, Francis JL. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost. 2003; 1:1972-1976.
33. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost. 2006; 96:816-821.
34. Stocking KL, Jones JC, Everds NE, Buetow BS, Roudier MP, Miller RE. Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells. Comp Med. 2009; 59:37-45.
35. Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood. 2014; 124:3183-3190.
36. Bastida E, Ordinas A. Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. Haemostasis. 1988; 18:29-36.
37. Tsuruo T, Fujita N. Platelet aggregation in the formation of tumor metastasis. Proc Jpn Acad Ser B Phys Biol Sci. 2008; 84:189-198.
38. Fujita N, Takagi S. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. J Biochem. 2012; 152:407-413.
39. Nakashima Y, Yoshinaga K, Kitao H, Ando K, Kimura Y, Saeki H, Oki E, Morita M, Kakeji Y, Hirahashi M, Oda Y, Maehara Y. Podoplanin is expressed at the invasive front of esophageal squamous cell carcinomas and is involved in collective cell invasion. Cancer Sci. 2013; 104:1718-1725.
40. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 2006; 119:4541-4553.
41. Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H, Detmar M. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol. 2010; 177:1004-1016.
42. Seki S, Fujiwara M, Matsuura M, Fujita S, Ikeda H, Umeda M, Asahina I, Ikeda T. Prognostic value of podoplanin expression in oral squamous cell carcinoma-a regression model auxiliary to UICC classification. Pathol Oncol Res. 2014; 20:521-528.
43. Hsieh JC, Lin HC, Huang CY, Hsu HL, Wu TM, Lee CL, Chen MC, Wang HM, Tseng CP. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head Neck. 2015; 37:1448-1455.
44. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K, Ochiai A. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer. 2008; 123:1053-1059.
45. Nakayama Y, Matsumoto K, Nagato M, Inoue Y, Katsuki T, Minagawa N, Shibao K, Tsurudome Y, Hirata K, Higure A, Sako T, Nagata N. Significance of lymphangiogenesis as assessed by immunohistochemistry for podoplanin in patients with esophageal carcinoma. Anticancer Res. 2007; 27:619-625.
46. Chao YK, Chuang WY, Yeh CJ, Wu YC, Liu YH, Hsieh MJ, Cheng AJ, Hsueh C, Liu HP. Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients. J Surg Oncol. 2012; 105:183-188.
47. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K, Osawa M. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun. 2006; 349:1301-1307.
48. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci. 2012; 103:1913-1919.
49. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol. 2013; 190:6239-6249.
50. Nakazawa Y, Takagi S, Sato S, Oh-hara T, Koike S, Takami M, Arai H, Fujita N. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci. 2011; 102:2051-2057.
51. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol. 2010; 37:785-794.
52. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer. 2013; 132:2339-2348.
53. Pandey A, Sarangi S, Chien K, Sengupta P, Papa AL, Basu S, Sengupta S. Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery. Nanotechnology. 2014; 25:445101.
54. Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure. 2014; 22:1711-1721.
55. Watson AA, Brown J, Harlos K, Eble JA, Walter TS, O'Callaghan CA. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. J Biol Chem. 2007; 282:3165-3172.
56. Jackson EC, Ortar G, McNicol A. The effects of an inhibitor of diglyceride lipase on collagen-induced platelet activation. J Pharmacol Exp Ther. 2013; 347:582-588.
57. Jiang A, Craxton A, Kurosaki T, Clark EA. Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med. 1998; 188:1297-1306.
58. Lau C, Wang X, Song L, North M, Wiehler S, Proud D, Chow CW. Syk associates with clathrin and mediates phosphatidylinositol 3-kinase activation during human rhinovirus internalization. J Immunol. 2008; 180:870-880.
59. Sidorenko SP, Law CL, Klaus SJ, Chandran KA, Takata M, Kurosaki T, Clark EA. Protein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signaling. Immunity. 1996; 5:353-363.
60. Chang CH, Chung CH, Hsu CC, Peng HC, Huang TF. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation. J Thromb Haemost. 2014; 12:540-549.
61. Lhermusier T, van Rottem J, Garcia C, Xuereb JM, Ragab A, Martin V, Gratacap MP, Sie P, Payrastre B. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost. 2011; 9:2067-2076.
62. Suram S, Brown GD, Ghosh M, Gordon S, Loper R, Taylor PR, Akira S, Uematsu S, Williams DL, Leslie CC. Regulation of cytosolic phospholipase A2 activation and cyclooxygenase 2 expression in macrophages by the beta-glucan receptor. J Biol Chem. 2006; 281:5506-5514.
63. Sato S, Fujita N, Tsuruo T. Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3. J Biol Chem. 2002; 277:39360-39367.
64. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012; 4:a011189.
65. Woulfe DS. Akt signaling in platelets and thrombosis. Expert Rev Hematol. 2010; 3:81-91.
66. Chen X, Zhang Y, Wang Y, Li D, Zhang L, Wang K, Luo X, Yang Z, Wu Y, Liu J. PDK1 regulates platelet activation and arterial thrombosis. Blood. 2013; 121:3718-3726.
67. Tsai HJ, Huang CL, Chang YW, Huang DY, Lin CC, Cooper JA, Cheng JC, Tseng CP. Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice. Arterioscler Thromb Vasc Biol. 2014; 34:2404-2412.
68. Tseng WL, Chen TH, Huang CC, Huang YH, Yeh CF, Tasi HJ, Lee HY, Kao CY, Lin SW, Liao HR, Cheng JC, Tseng CP. Impared thrombin generation in Reelin-deficient mice: a potential role of plasma Reelin in hemostasis. J Thromb Haemost. 2014; 12:2054-2064.
69. Tseng CP, Huang CH, Tseng CC, Lin MH, Hsieh JT, Tseng CH. Induction of disabled-2 gene during megakaryocyte differentiation of K562 cells. Biochem Biophys Res Commun. 2001; 285:129-135.